Synthetic cannabinoids further rift between marijuana and hemp industries

A recent ruling from the U.S. Drug Enforcement Administration classifying a synthetic cannabinoid as a Schedule 1 drug has furthered the ire between the licensed cannabis industry and the largely unregulated cannabinoid sector, which has grown into a multi-billion market amid the proliferation of CBD and Delta-lineage products since the passage of the 2018 Farm Bill.

Chart showing cannabinoid market breakdown